The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
“Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis ... and lower sweat chloride levels than TRIKAFTA, is another step in achieving this goal.” ...
LCI proves valuable in monitoring ETI therapy effectiveness for cystic fibrosis patients with minimal FEV1 changes, detecting ...
A $42,000 grant from NASA and INBRE will further CF research, through a collaborative effort spanning to India and the United Kingdom.
Trikafta can treat approximately 90% of CF patients and ... is a commercial-stage biopharmaceutical with a core franchise of ...
The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...
Throughout Gunnar Esiason's journey with cystic fibrosis, the sport of hockey has always been huge part of his family. See ...
The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared ...
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback